Neurological Disorder Drugs Market Report 2026

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $89.24 billion in 2025 to $94.49 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising prevalence of epilepsy and neurodegenerative diseases, aging global population, long-term use of symptomatic neurological drugs, expansion of hospital-based neurological care, increased diagnosis rates of neurological disorders.

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $116.27 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to advancements in neurological drug development pipelines, growing burden of alzheimer’s and parkinson’s disease, increasing access to neurological care in emerging markets, rising demand for personalized neurology treatments, expansion of homecare and outpatient neurological therapy. Major trends in the forecast period include growing adoption of disease-modifying neurological therapies, rising focus on early diagnosis and long-term disease management, increased demand for combination drug therapies, expansion of oral and home-based neurological treatments, higher emphasis on symptom management and quality of life improvement.

The rising prevalence of neurological diseases is anticipated to drive the expansion of the neurological disorder drugs market in the coming years. Neurological disorders are conditions that impact the brain, spinal cord, and nerves due to structural, biochemical, or electrical irregularities, resulting in a variety of symptoms. The growth in neurological diseases is linked to the aging global population as well as increased exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs are essential in managing these complex conditions, providing symptom relief, slowing disease progression, and enhancing long-term patient outcomes. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, rising from approximately 411,100 in 2023 to 849,300 by 2058, with about 315,500 men and 533,800 women affected. Consequently, the rising prevalence of neurological diseases is fueling the growth of the neurological disorder drugs market.

Major companies operating in the neurological disorder drugs market are concentrating on developing advanced solutions such as Ocrelizumab-based therapies to boost treatment effectiveness, enhance patient outcomes, and broaden therapeutic choices for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody engineered to target CD20-positive B cells, helping to reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For example, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, obtained regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), a twice-yearly, roughly 10-minute subcutaneous injection, representing the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This improved delivery option is intended to enhance convenience, increase access to therapy, and support clinical workflow efficiency by providing a faster, non-intravenous method of administration.

In March 2024, Bristol-Myers Squibb Company (BMS), a US-based pharmaceutical firm, acquired Karuna Therapeutics Inc. for an undisclosed sum. With this acquisition, BMS intends to enhance its global neuroscience portfolio by obtaining Karuna’s lead asset KarXT (xanomeline-trospium), a first-in-class muscarinic receptor modulator being developed for neurological and psychiatric disorders such as schizophrenia and Alzheimer’s disease-related psychosis. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on innovative therapies for neurological and neuropsychiatric conditions.

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurological disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the neurological disorder drugs market by increasing costs for imported active pharmaceutical ingredients, intermediates, and specialized formulation materials. These impacts are most significant in regions reliant on cross-border pharmaceutical supply chains, including North America and Europe. Higher tariffs have affected pricing and availability across antiepileptic and neurodegenerative drug segments. However, tariffs have also encouraged local manufacturing, domestic API production, and supply chain diversification, supporting long-term market stability.

The neurological disorder drugs market research report is one of a series of new reports that provides neurological disorder drugs market statistics, including neurological disorder drugs industry global market size, regional shares, competitors with a neurological disorder drugs market share, detailed neurological disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. This neurological disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurological disorder drugs are medications designed to treat conditions affecting the nervous system. These conditions can impact the brain, spinal cord, and nerves throughout the body. The medications work to control symptoms, slow disease progression, and enhance the quality of life for those affected.

The main categories of drugs used in neurological disorders include cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors are drugs that inhibit the breakdown of acetylcholine, a neurotransmitter essential for memory and cognitive function. These medications can be applied for multiple indications, such as epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular disease, and more, and are available through various routes of administration, including oral, parenteral, and others. They can be supplied through different distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, with end users including hospitals, specialty clinics, home care, and more.

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.